Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06012916 · ClinicalTrials.gov registry record

Brain Network Dynamics of Depression During Esketamine Treatment

A clinical trial of Depressive Disorder, Major, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
8
Enrollment target
1
Study location

NCT06012916: Completed study of Depressive Disorder, Major, sponsored by University of North Carolina, Chapel Hill.

NCT06012916 is a study of Depressive Disorder, Major that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 8 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06012916, a study of Depressive Disorder, Major, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
8 participants
Enrollment target
1
Study location

Study Summary

This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief updating and the relation of those effects on depressive symptomatology.

Primary Outcome

Participants rate the likelihood of a negative life event happening to them (E1) and their confidence in the estimate (C1). They are given a base rate (BR), described as the average lifetime probability of that event happening to someone with the same demographics. Participants will then again rate how likely the event could happen to them personally (E2). Outcome variables: update = \|E2 - E1\| and estimation error (ER) = \|E1 - BR\| News: "good news" (BR\< E1) or "bad news" (BR\>E1) trials.

Conditions Studied

Depressive Disorder, Major

Interventions

  • DRUG Esketamine nasal spray

Study Locations (1)

North Carolina

  • Carolina Center for Neurostimulation - Chapel Hill

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2023-07-03
Est. Completion 2024-08-30
University of North Carolina, Chapel Hill

1,109 total trials

What the finished NCT06012916 record still lists

NCT06012916 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Esketamine nasal spray is the first listed.

NCT06012916 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06012916 about?

NCT06012916 is a clinical study titled "Brain Network Dynamics of Depression During Esketamine Treatment". This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief upd...

What is the current status of trial NCT06012916?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2023-07-03. Estimated completion is 2024-08-30.

What conditions does trial NCT06012916 study?

This clinical trial studies the following conditions: Depressive Disorder, Major.

What interventions are being tested in trial NCT06012916?

The interventions under investigation include: Esketamine nasal spray (DRUG).

Who is sponsoring clinical trial NCT06012916?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06012916 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depressive Disorder, Major

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06012916's enrollment target sits among peer trials

8 53rd of 52 the lowest of 52 other Depressive Disorder, Major trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06012916, the US trial registry maintained by the National Library of Medicine. NCT06012916 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.